On March 15, 2021 Immodulon, the immuno-oncology company, reported that its Chief Scientific Officer, Dr. Thomas Kleen, will present at the 11th World Clinical Biomarkers & Companion Diagnostic Europe Event taking place virtually 24-25 March 2021 (Press release, Immodulon Therapeutics, MAR 15, 2021, View Source [SID1234576647]). The presentation, titled ‘Clinical Biomarker Strategy with a Complex Immunomodulator: The Must-Haves & the Nice-To-Haves On a Limited Budget’, will be presented at 12:45 CET, 25 March.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will discuss several topics including the challenges posed by the identification and validation of various circulatory immunological biomarkers in cancer patients during clinical trials, and the benefits and challenges of using novel technologies and classic immunological biomarkers.
11th World Clinical Biomarkers & Companion Diagnostic Europe Event
The annual Clinical Biomarkers & CDx Europe Summit brings stakeholders together to fast-track precision medicine through clinically validated biomarkers and companion diagnostics partnerships in Europe. The meeting will tackle key conversations spanning biomarker discovery through to drug-Dx market penetration, enabling innovation to power pipeline progression. Featuring the latest tools and techniques validating biomarker utility, overcoming patient selection challenges in rare disease, key clinical case-study learnings shaping diagnostic strategy in addition to the much needed core EU focus on navigating a tricky regulatory and reimbursement landscape to prevent incoming regulations hindering the delivery of critical drugs to patients in need. Find out more at www.worldcdxeurope.com